Startup profile · funding coverage
Matchpoint Therapeutics funding, valuation and investors
Precision covalent medicines for autoimmune and inflammatory diseases.
Keep track of Matchpoint Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$150M · October 7, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$150M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Watertown, Massachusetts, United States
Investors in latest funding
Lead: Nextech Invest , Norwest
Other: Invus , BB Biotech , T1D Fund , BOLD Longevity Growth , Access Biotechnology , Atlas Venture , Sanofi Ventures , Digitalis Ventures
Overview
Matchpoint Therapeutics is a Watertown, Massachusetts biotechnology company developing rationally designed covalent small molecules against biologically validated but historically difficult drug targets. Its lead program, MPT-062, is an oral T-cell modulator expected to enter clinical development in 2027.
Why Matchpoint Therapeutics is interesting
Matchpoint combines chemical biology, covalent chemistry, structure-based design and computation in a platform that has already attracted a Novartis collaboration and a large preclinical Series B.
Product & use cases
The company’s ACE discovery engine generates covalent small molecules. MPT-062 is designed to modulate disease-causing T-cell overactivation in autoimmune and inflammatory conditions.
- Oral treatment of autoimmune and inflammatory diseases
- Discovery of precision covalent medicines for hard-to-drug targets
Key facts
- Closed a $150 million Series B in October 2026.
- Has a separate discovery collaboration funded by Novartis.
Funding history (newest first)
Series B
2026-10-07 $150M- Nextech Invest (lead)
- Norwest (lead)
- Invus (participant)
- BB Biotech (participant)
- T1D Fund (participant)
- BOLD Longevity Growth (participant)
- Access Biotechnology (participant)
- Atlas Venture (participant)
- Sanofi Ventures (participant)
- Digitalis Ventures (participant)
Investors in our directory
Funds linked from Matchpoint Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A focused covalent-chemistry platform aimed at durable engagement of validated targets that have resisted conventional small molecules.
Matchpoint competes with internal pharma discovery programs and specialist covalent-drug platforms. Its near-term differentiation depends on translating preclinical chemistry into clinical proof of concept.
-
Enlaza Therapeutics adjacent
Develops covalent biologics rather than oral small molecules.
-
Covant Therapeutics direct
Uses covalent chemistry to address difficult disease targets.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Matchpoint Therapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.